be affected by the development activities. In addition, the Trust Resources Planning Alternative would establish thresholds needed to achieve these goals and objectives, including, for example, conditions of approval and design requirements that may be attached to future development authorizations.

The BLM welcomes comments on all preliminary alternatives, as well as suggestions for additional alternatives.

Summary of Expected Impacts

The BLM and the Tribe currently anticipate an increase in exploration and development of Tribal trust minerals within the Mancos Shale formation within the planning area. The environmental effects associated with this exploration and development may include, among other effects, impacts to air quality; water quality/quantity; traffic; vegetation; fish and wildlife; cultural, historic, and archaeological resources; noise, light, and visual resources; and economic resources. These potential impacts will be analyzed in the Programmatic EIS.

Anticipated Permits and Authorizations

The BLM and the Tribe do not anticipate that any site-specific approvals or ground-disturbing authorizations will be granted as part of this agency action. Rather, it is anticipated that the BLM and the Tribe will establish goals and objectives in the best interests of the Tribe for the management of Tribal trust minerals within the planning area, as well as measures needed to achieve those goals and objectives. The Federal agency actions under consideration concern the use of Tribal trust property, not Federal public lands or minerals; no Federal public lands or minerals not held in trust are located within the planning area.

Schedule for the Decision-Making Process

The Final Programmatic EIS and Record of Decision are expected on or prior to June 2028. This Programmatic EIS is subject to the deadlines set forth at 42 U.S.C. 4336a(g)(1)(A).

Public Scoping Process

This notice of intent initiates the scoping period. The Tribe and the BLM will be holding an in-person scoping meeting on September 24, 2026, from 6 p.m. to 8:30 p.m. Mountain Time, at the Sky Ute Casino, at 14324 US Highway 172 North, Ignacio, Colorado 81301, from 6 p.m. to 8:30 p.m. The Tribe and the BLM will also accept written scoping comments.

Responsible Official

The BLM Colorado Southwest District Manager is the deciding official for the BLM. The Southern Ute Indian Tribe is a joint lead agency pursuant to 42 U.S.C. 4336a(a)(1)(B). The Tribal representatives will be the deciding officials for the Southern Ute Indian Tribe.

Nature of Decision To Be Made

The BLM and the Tribe intend to establish goals and objectives in the best interests of the Tribe for the management of Tribal trust minerals within the planning area, and measures intended to support and achieve those goals and objectives.

Additional Information

The BLM will utilize and coordinate the NEPA process to help support compliance with applicable procedural requirements under the Endangered Species Act (16 U.S.C. 1536) and section 106 of the National Historic Preservation Act (54 U.S.C. 306108) as provided in 36 CFR 800.2(d)(3), including public involvement requirements of section 106. The information about historic and cultural resources and threatened and endangered species within the area potentially affected by the proposed project will assist the BLM in identifying and evaluating impacts to such resources.

The BLM will consult with Indian Tribal Nations on a government-to-government basis in accordance with Executive Order 13175, BLM Manual Section 1780, and other Departmental policies. Tribal concerns, including impacts on Indian trust assets and potential impacts to cultural resources, will be given due consideration. Federal, State, and local agencies, along with Indian Tribal Nations and other stakeholders that may be interested in or affected by the proposed planning decisions for oil and gas operations that the BLM is evaluating, are invited to participate in the scoping process and, if eligible, may request or be requested by the BLM to participate in the development of the environmental analysis as a Cooperating Agency.

Before including your address, phone number, email address, or other personal identifying information in your comment, you should be aware that your entire comment—including your personal identifying information—may be made publicly available at any time. While you can ask us in your comment to withhold your personal identifying information from public review, we cannot guarantee that we will be able to do so.

(Authority: 43 CFR 1610.2.)

Thomas Heinlein,

BLM Colorado Acting State Director.

[FR Doc. 2026–18106 Filed 9–3–26; 8:45 am]

BILLING CODE 4331–16–P

INTERNATIONAL TRADE COMMISSION

[Investigation No. 337–TA–1501]

Certain Coated Confectionery Products and Components Thereof; Notice of Commission Determination Not To Review an Initial Determination Granting Complainant's Unopposed Motion To Amend the Complaint and Notice of Investigation

AGENCY: U.S. International Trade Commission.

ACTION: Notice.

SUMMARY: Notice is hereby given that the U.S. International Trade Commission has determined not to review an initial determination (''ID'') (Order No. 7) of the presiding Administrative Law Judge (''ALJ'') granting complainant's unopposed motion to amend the complaint and notice of investigation to add AnaBio Technologies Unlimited Company of Dublin, Ireland, as a respondent (''Added Respondent'') and to terminate respondent AnaBio Technologies, LTD. of Dublin, Ireland (''Terminated Respondent'').

FOR FURTHER INFORMATION CONTACT: Houda Morad, Esq., Office of the General Counsel, U.S. International Trade Commission, 500 E Street SW, Washington, DC 20436, telephone (202) 708–4716. Copies of non-confidential documents filed in connection with this investigation may be viewed on the Commission's electronic docket (EDIS) at *https://edis.usitc.gov.* For help accessing EDIS, please email *EDIS3Help@usitc.gov.* General information concerning the Commission may also be obtained by accessing its internet server at *https://www.usitc.gov.* Hearing-impaired persons are advised that information on this matter can be obtained by contacting the Commission's TDD terminal on (202) 205–1810.

SUPPLEMENTARY INFORMATION: The Commission instituted this investigation on June 1, 2026, based on a complaint filed by Promotion in Motion, Inc. (''Complainant'') of Park Ridge, New Jersey. 91 FR 32434 (June 1, 2026). The complaint, as supplemented, alleges violations of section 337 of the Tariff Act of 1930, as amended, 19 U.S.C.

1337, in the importation into the United States, the sale for importation, or the sale within the United States after importation of certain coated confectionery products and components thereof by reason of infringement of certain claims of U.S. Patent Nos. 9,750,267 and 11,317,640. *Id.* The complaint further alleges that a domestic industry exists or is in the process of being established. *Id.* In addition to the Terminated Respondent, the notice of investigation named the following respondents: Cibo Vita, Inc. of Totowa, New Jersey; Cibo Vita Founders, Inc. of Wilmington, Delaware; and New Cibo Vita, LLC of Wilmington, Delaware (collectively, ''Respondents''). *Id.* The Office of Unfair Import Investigations is not participating in the investigation. *Id.*

On July 30, 2026, Complainant filed a motion to amend the complaint and notice of investigation to add the Added Respondent and to terminate the Terminated Respondent. The motion states that Respondents do not oppose the motion.

On August 3, 2026, the ALJ issued the subject ID (Order No. 7) granting the motion pursuant to Commission Rule 210.21(a)(1) and 210.14(b), 19 CFR 210.21(a)(1) and 210.14(b). In accordance with Commission Rule 210.21(a)(1), the ID notes that ''there are no agreements written or oral, express or implied . . . between Complainant and the Terminated Respondent.'' ID at 4. In addition, the ID finds good cause under Commission Rule 210.14(b) for adding the Added Respondent because the ''identification of the substitute entity was based on information obtained during discovery.'' *Id.* The ID also finds no prejudice to the public interest or the rights of the parties participating in this investigation. *Id.* at 5. The ID explains that the proposed amendment ''will not necessitate a change in the substantive scope of the investigation because the proposed amendment is essentially a substitution.'' *Id.* The ID further finds that ''the investigation is still in relatively early stages and there are several months remaining in fact discovery.'' *Id.*

No petition for review of the subject ID was filed.

The Commission has determined not to review the subject ID. AnaBio Technologies Unlimited Company is added as a respondent in this investigation, and AnaBio Technologies, LTD. is terminated from the investigation.

The Commission vote for this determination took place on September 1, 2026.

The authority for the Commission's determination is contained in section 337 of the Tariff Act of 1930, as amended (19 U.S.C. 1337), and in Part 210 of the Commission's Rules of Practice and Procedure (19 CFR part 210).

By order of the Commission.

Issued: September 1, 2026.

Lisa Barton,

Secretary to the Commission.

[FR Doc. 2026–18102 Filed 9–3–26; 8:45 am]

BILLING CODE 7020–02–P

INTERNATIONAL TRADE COMMISSION

[Investigation No. 337–TA–1411]

Certain Photodynamic Therapy Systems, Components Thereof, and Pharmaceutical Products Used in Combination With the Same; Notice of the Commission's Determination To Lift the Partial Suspension of Enforcement of the Remedial Orders as to U.S. Patent No. 11,697,028

AGENCY: U.S. International Trade Commission.

ACTION: Notice.

SUMMARY: Notice is hereby given that the U.S. International Trade Commission (''Commission'') has determined to grant a request submitted by Sun Pharmaceutical Industries, Inc. (''Complainant'') of Princeton, New Jersey to lift the partial suspension of enforcement of the limited exclusion order (''LEO'') and cease and desist orders (''CDOs'') as to U.S. Patent No. 11,697,028 (''the '028 patent'').

FOR FURTHER INFORMATION CONTACT: B. Rashmi Borah, Esq., Office of the General Counsel, U.S. International Trade Commission, 500 E Street SW, Washington, DC 20436, telephone (202) 205–2518. Copies of non-confidential documents filed in connection with this investigation may be viewed on the Commission's electronic docket (EDIS) at *https://edis.usitc.gov.* For help accessing EDIS, please email *EDIS3Help@usitc.gov.* General information concerning the Commission may also be obtained by accessing its internet server at *https://www.usitc.gov.* Hearing-impaired persons are advised that information on this matter can be obtained by contacting the Commission's TDD terminal on (202) 205–1810.

SUPPLEMENTARY INFORMATION: The Commission instituted this investigation on August 1, 2024, based on a complaint filed by Complainant. 89 FR 62790 (Aug. 1, 2024). The complaint, as supplemented, alleges violations of section 337 of the Tariff Act of 1930, as amended, 19 U.S.C. 1337, based on the importation into the United States, the sale for importation, and the sale within the United States after importation of certain photodynamic therapy systems, components thereof, and pharmaceutical products used in combination with the same by reason of infringement of certain claims of the U.S. Patent Nos. 11,446,512 (''the '512 patent'') and the '028 patent. *Id.* The complaint further alleges that a domestic industry exists or is in the process of being established. *Id.* The notice of investigation names Respondents as respondents. *Id.* The Office of Unfair Import Investigations was not a party to this investigation. *Id.*

On September 30, 2026, the presiding administrative law judge issued a final initial determination (''FID'') finding a violation of section 337 with respect to each of the asserted claims. As relevant to the subject request, the FID finds that the asserted claims of the '028 patent are not invalid as obvious.

On January 28, 2026, the Commission determined to review the FID in part. 91 FR 4630 (Feb. 2, 2026). As relevant to the current request, the Commission determined to review the FID's finding that the asserted claims of the '028 patent are not invalid as obvious.

On February 23, 2026, the Patent Trial and Appeal Board issued a final written decision (''FWD'') finding all asserted claims of the '028 patent invalid as obvious.

On May 6, 2026, the Commission issued a final determination finding a violation of section 337 by Respondents with respect to all remaining asserted claims. 91 FR 25595–96 (May 11, 2026). As relevant to the subject request, the Commission affirmed the FID's finding that the asserted claims of the '028 patent are not invalid as obvious and found a violation of section 337 as to the '028 patent and the '512 patent. *Id.* at 25596. The Commission determined to issue an LEO and CDOs as to each of Respondents and also set a bond in the amount of zero percent during the period of Presidential review. *Id.* However, the Commission suspended enforcement of the remedial orders in part upon issuance as to the '028 patent, in light of the FWD. *Id.*

On July 29, 2026, the Director of the United States Patent and Trademark Office issued an order vacating the FWD in its entirety. *See Biofrontera Inc. et al.* v. *Sun Pharm. Indus. Inc.,* IPR2024–01312, Paper No. 58 (Order) (July 29, 2026).

On July 31, 2026, Complainant submitted a letter requesting that the